Heparin prodrugs and drug delivery stents formed therefrom

Patent metadata

Field	Value
Publication number	US-9375445-B2
Application number	US-48920509-A
Country	US
Kind code	B2
Filing date	Jun 22, 2009
Priority date	Jun 18, 2004
Publication date	Jun 28, 2016
Grant date	Jun 28, 2016

Abstract

A prodrug comprising a heparin and a drug is provided. The prodrug can be used to form a coating on a medical device. The prodrug can also be used with a polymeric material to form a coating on a medical device. The polymeric material can be a hydrophobic polymer, a hydrophilic polymer, a non-fouling polymer, or combinations thereof. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

First claim

What is claimed is:

1. A coating composition comprising:
a prodrug, the prodrug comprising a drug, heparin, and a first polymer,
wherein the heparin is linked covalently to the first polymer and the drug,
wherein the covalent linkage between the drug and the heparin is either hydrolytically or enzymatically unstable,
wherein the drug is not pharmacologically active when linked to the heparin, and
wherein the first polymer is selected from the group consisting of poly(L-lysine-co-hyaluronic acid) (PLL-co-HA), poly(L-lysine-co-phosphoryl choline) (PLL-co-PC), poly(ethylimine-co-hyaluronic acid) (PEI-co-HA), poly(ethylimine-co-phosphoryl choline) (PEI-co-PC), poly(L-lysine-g-hyaluronic acid) (PLL-g-HA), poly(L-lysine-g-phosphoryl choline) (PLL-g-PC), poly(ethylimine-g-hyaluronic acid) (PEI-g-HA), and poly(ethylimine-g-phosphoryl choline) (PEI-g-PC).

2. The composition of claim 1 , wherein the drug is selected from the group consisting of antiproliferative, anti-inflammatory, non-steroidal anti-inflammatory, and antimitotic drugs and combinations thereof.

3. The composition of claim 2 , wherein the drug is selected from the group consisting of paclitaxel, docetaxel, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, (ABT-578, zotarolimus) and combinations thereof.

4. The composition of claim 3 , wherein the heparin is a pentasaccharide.

5. The composition of claim 3 , further comprising a second polymer selected from the group consisting of a hydrophilic polymer, a hydrophobic polymer, a non-fouling polymer, and combinations thereof.

6. The composition of claim 1 , wherein the drug is linked directly to the first polymer.

7. The composition of claim 1 , wherein the heparin is a pentasaccharide.

8. The composition of claim 7 , further comprising a second polymer selected from the group consisting of a hydrophilic polymer, a hydrophobic polymer, a non-fouling polymer, and combinations thereof.

9. The composition of claim 1 , further comprising a second polymer selected from the group consisting of a hydrophilic polymer, a hydrophobic polymer, a non-fouling polymer, and combinations thereof.

Assignees

• Hossainy Syed Faiyaz Ahmed
• Ding Ni
• Abbott Cardiovascular Systems

Inventors

• Hossainy Syed Faiyaz Ahmed
• Ding Ni

Classifications

• A61L2300/80

  characterised by a special chemical form · CPC title

• C09D105/10

  Heparin; Derivatives thereof · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• C08B37/0075

  Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof · CPC title

• A61K31/727 Primary

  Heparin; Heparan · CPC title